Article List
List all articles in the database by earliest discovery_date
GET /articles/?format=api&page=2395
{ "count": 24781, "next": "http://api.gregory-ms.com/articles/?format=api&page=2396", "previous": "http://api.gregory-ms.com/articles/?format=api&page=2394", "results": [ { "article_id": 850, "title": "Compensatory image of the stability of people with multiple sclerosis and atrial vertigo based on posturography examination", "summary": "<div><p>Sci Rep. 2021 Mar 29;11(1):7027. doi: 10.1038/s41598-021-85983-z.</p><p><b>ABSTRACT</b></p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">Pathophysiology of balance disorders due to multiple sclerosis (MS) and atrial vertigo (AV) is different. We evaluated posture stability when maintaining balance in people with MS presenting symptoms of ataxia and those with AV. We included 45 women (15 with MS; 15 with AV; 15 controls). A posturography platform was used to measure balance parameters. To characterize the image of stability and the compensation of balance disorders, the surface area of the stabilogram (SAS), vision control index (VCI) and the vision-motion control index (VMCI) were used. The stability image of people with MS and AV with eyes open (p = 0.002), with eyes closed (p = 0.080) and with visual biofeedback (p = 0.0008) differed significantly. SAS depended on visual biofeedback regardless of the occurrence of balance disorders and was the basis for determining the compensatory share of vision-motor coordination. Differences in VCI between groups were insignificant. VMCI was significantly higher in people with balance disorders than in those without, but similar in the MS and AV groups. The image of stability is different in people with MS and AV. Thanks to visual biofeedback, it becomes possible to launch effective vision-motor coordination when compensating balance disorders. VCI may become the measure of compensation for balance disorders.</p><p>PMID:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33782416/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210330132823&v=2.14.3\">33782416</a> | DOI:<a href=\"https://doi.org/10.1038/s41598-021-85983-z\">10.1038/s41598-021-85983-z</a></p></div>", "link": "https://pubmed.ncbi.nlm.nih.gov/33782416/#x3D;Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc&#x", "published_date": "2021-03-28T23:00:00Z", "sources": [ "PubMed" ], "teams": [ { "id": 1, "name": "Team Gregory" } ], "subjects": [ { "subject_name": "Multiple Sclerosis", "description": null } ], "publisher": "Springer Science and Business Media LLC", "container_title": "Scientific Reports", "authors": [ { "author_id": 247081, "given_name": "Oliwer", "family_name": "Kahl", "ORCID": null, "country": null }, { "author_id": 247083, "given_name": "Ewelina", "family_name": "Wierzbicka", "ORCID": null, "country": null }, { "author_id": 247085, "given_name": "Magdalena", "family_name": "Dębińska", "ORCID": null, "country": null }, { "author_id": 247087, "given_name": "Maciej", "family_name": "Mraz", "ORCID": null, "country": null }, { "author_id": 247089, "given_name": "Małgorzata", "family_name": "Mraz", "ORCID": null, "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2021-03-30T17:28:24Z", "noun_phrases": [ "Compensatory image", "the stability", "people", "multiple sclerosis", "posturography examination" ], "doi": "10.1038/s41598-021-85983-z", "access": "open", "takeaways": " The image of stability is different in people with MS and AV . VCI may become the measure of compensation for balance disorders . Thanks to visual biofeedback, it becomes possible to launch effective vision-motor coordination .", "categories": [] }, { "article_id": 847, "title": "The NLRP3 inflammasome: an emerging therapeutic target for chronic pain", "summary": "AbstractChronic pain affects the life quality of the suffering patients and posts heavy problems to the health care system. Conventional medications are usually insufficient for chronic pain management and oftentimes results in many adverse effects. The NLRP3 inflammasome controls the processing of proinflammatory cytokine interleukin 1β (IL-1β) and is implicated in a variety of disease conditions. Recently, growing number of evidence suggests that NLRP3 inflammasome is dysregulated under chronic pain condition and contributes to pathogenesis of chronic pain. This review provides an up-to-date summary of the recent findings of the involvement of NLRP3 inflammasome in chronic pain and discussed the expression and regulation of NLRP3 inflammasome-related signaling components in chronic pain conditions. This review also summarized the successful therapeutic approaches that target against NLRP3 inflammasome for chronic pain treatment.", "link": "https://jneuroinflammation.biomedcentral.com/articles/10.1186/s12974-021-02131-0", "published_date": "2021-03-29T23:00:00Z", "sources": [ "BioMedCentral" ], "teams": [ { "id": 1, "name": "Team Gregory" } ], "subjects": [ { "subject_name": "Multiple Sclerosis", "description": null } ], "publisher": "Springer Science and Business Media LLC", "container_title": "Journal of Neuroinflammation", "authors": [ { "author_id": 287123, "given_name": "Ruixiang", "family_name": "Chen", "ORCID": null, "country": null }, { "author_id": 287124, "given_name": "Chengyu", "family_name": "Yin", "ORCID": null, "country": null }, { "author_id": 287126, "given_name": "Jianqiao", "family_name": "Fang", "ORCID": null, "country": null }, { "author_id": 187530, "given_name": "Boyi", "family_name": "Liu", "ORCID": "http://orcid.org/0000-0001-9870-4548", "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2021-03-30T14:43:54Z", "noun_phrases": [ "The NLRP3 inflammasome", "an emerging therapeutic target", "chronic pain" ], "doi": "10.1186/s12974-021-02131-0", "access": "open", "takeaways": " The NLRP3 inflammasome controls the processing of proinflammatory cytokine interleukin 1β (IL-1β) and is implicated in a variety of disease conditions . Growing number of evidence suggests that NLRP1 is dysregulated under chronic pain condition and contributes to pathogenesis of chronic", "categories": [] }, { "article_id": 846, "title": "Neurological manifestations and complications of coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis", "summary": "Background: The spectrum of neurological involvement in COVID-19 is not thoroughly understood. To the best of our knowledge, no systematic review with meta-analysis and a sub-group comparison between severe and non-severe cases has been published. The aim of this study is to assess the frequency of neurological manifestations and complications, identify the neurodiagnostic findings, and compare these aspects between severe and non-severe COVID-19 cases.MethodsA systematic search of PubMed, Scopus, EBSCO, Web of Science, and Google Scholar databases was conducted for studies published between the 1st of January 2020 and 22nd of April 2020. In addition, we scanned the bibliography of included studies to identify other potentially eligible studies. The criteria for eligibility included studies published in English language (or translated to English), those involving patients with COVID-19 of all age groups, and reporting neurological findings. Data were extracted from eligible studies. Meta-analyses were conducted using comprehensive meta-analysis software. Random-effects model was used to calculate the pooled percentages and means with their 95% confidence intervals (CIs). Sensitivity analysis was performed to assess the effect of individual studies on the summary estimate. A subgroup analysis was conducted according to severity. The main outcomes of the study were to identify the frequency and nature of neurological manifestations and complications, and the neuro-diagnostic findings in COVID-19 patients.Results44 articles were included with a pooled sample size of 13,480 patients. The mean age was 50.3 years and 53% were males. The most common neurological manifestations were: Myalgia (22.2, 95% CI, 17.2 to 28.1%), taste impairment (19.6, 95% CI, 3.8 to 60.1%), smell impairment (18.3, 95% CI, 15.4 to 76.2%), headache (12.1, 95% CI, 9.1 to 15.8%), dizziness (11.3, 95% CI, 8.5 to 15.0%), and encephalopathy (9.4, 95% CI, 2.8 to 26.6%). Nearly 2.5% (95% CI, 1 to 6.1%) of patients had acute cerebrovascular diseases (CVD). Myalgia, elevated CK and LDH, and acute CVD were significantly more common in severe cases. Moreover, 20 case reports were assessed qualitatively, and their data presented separately.ConclusionsNeurological involvement is common in COVID-19 patients. Early recognition and vigilance of such involvement might impact their overall outcomes.", "link": "https://bmcneurol.biomedcentral.com/articles/10.1186/s12883-021-02161-4", "published_date": "2021-03-29T23:00:00Z", "sources": [ "BioMedCentral" ], "teams": [ { "id": 1, "name": "Team Gregory" } ], "subjects": [ { "subject_name": "Multiple Sclerosis", "description": null } ], "publisher": "Springer Science and Business Media LLC", "container_title": "BMC Neurology", "authors": [ { "author_id": 152519, "given_name": "Ahmed", "family_name": "Yassin", "ORCID": "http://orcid.org/0000-0002-3175-0408", "country": null }, { "author_id": 247033, "given_name": "Mohammed", "family_name": "Nawaiseh", "ORCID": null, "country": null }, { "author_id": 247034, "given_name": "Ala", "family_name": "Shaban", "ORCID": null, "country": null }, { "author_id": 247035, "given_name": "Khalid", "family_name": "Alsherbini", "ORCID": null, "country": null }, { "author_id": 151199, "given_name": "Khalid", "family_name": "El-Salem", "ORCID": "http://orcid.org/0000-0002-8163-5256", "country": null }, { "author_id": 247036, "given_name": "Ola", "family_name": "Soudah", "ORCID": null, "country": null }, { "author_id": 188347, "given_name": "Mohammad", "family_name": "Abu-Rub", "ORCID": "http://orcid.org/0000-0003-3318-0522", "country": null } ], "relevant": false, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2021-03-30T11:48:54Z", "noun_phrases": [ "Neurological manifestations", "complications", "coronavirus disease", "COVID-19", "a systematic review", "meta-analysis" ], "doi": "10.1186/s12883-021-02161-4", "access": "open", "takeaways": " The spectrum of neurological involvement in COVID-19 is not thoroughly understood . Aim of this study is to assess the frequency of neurological manifestations and complications, and compare these aspects between severe and non-severe cases . Myalgia, elevated CK and LDH, and acute CVD were significantly more common in severe cases .", "categories": [] }, { "article_id": 842, "title": "Low-field portable brain MRI in CNS demyelinating disease", "summary": "<div><p>Mult Scler Relat Disord. 2021 Mar 18;51:102903. doi: 10.1016/j.msard.2021.102903. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">A low-field (0.2 Tesla), portable MRI scanner has been developed that may address barriers to MRI for people with multiple sclerosis (MS). As a proof of concept study, we imaged two participants with central nervous system demyelinating disease by both a standard 1.5 Tesla MRI and the portable MRI scanner. These images demonstrate the ability to identify a solitary demyelinating lesion in early stage disease and cortical atrophy and chronic white matter changes in late stage disease. In spite of device limitations, including border distortion and lower image quality, the portable device has important implications for addressing barriers to care in people with MS.</p><p>PMID:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33780808/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210330012823&v=2.14.3\">33780808</a> | DOI:<a href=\"https://doi.org/10.1016/j.msard.2021.102903\">10.1016/j.msard.2021.102903</a></p></div>", "link": "https://pubmed.ncbi.nlm.nih.gov/33780808/#x3D;Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc&#x", "published_date": "2021-01-06T00:00:00Z", "sources": [ "PubMed" ], "teams": [ { "id": 1, "name": "Team Gregory" } ], "subjects": [ { "subject_name": "Multiple Sclerosis", "description": null } ], "publisher": "Elsevier BV", "container_title": "Multiple Sclerosis and Related Disorders", "authors": [ { "author_id": 253636, "given_name": "Farrah J.", "family_name": "Mateen", "ORCID": null, "country": null }, { "author_id": 183358, "given_name": "Clarissa Zimmerman", "family_name": "Cooley", "ORCID": "http://orcid.org/0000-0001-8691-9373", "country": null }, { "author_id": 282840, "given_name": "Jason P.", "family_name": "Stockmann", "ORCID": null, "country": null }, { "author_id": 180853, "given_name": "Dylan R", "family_name": "Rice", "ORCID": "http://orcid.org/0000-0002-0295-1462", "country": null }, { "author_id": 268394, "given_name": "Andre C.", "family_name": "Vogel", "ORCID": null, "country": null }, { "author_id": 282841, "given_name": "Lawrence L.", "family_name": "Wald", "ORCID": null, "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2021-03-30T05:28:24Z", "noun_phrases": [ "Low-field portable brain MRI", "CNS demyelinating disease" ], "doi": "10.1016/j.msard.2021.102903", "access": "restricted", "takeaways": " Low-field (0.2 Tesla), portable MRI scanner has been developed that may address barriers to MRI for people with multiple sclerosis .", "categories": [] }, { "article_id": 843, "title": "Depression in multiple sclerosis: Is one approach for its management enough?", "summary": "<div><p>Mult Scler Relat Disord. 2021 Mar 18;51:102904. doi: 10.1016/j.msard.2021.102904. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">BACKGROUND: Major depression disorder (MDD) and severe depression symptoms are highly prevalent in multiple sclerosis (MS). Depression can worsen symptoms of MS and is associated with significantly reduced quality of life and increased risk of suicide. Currently, there is no gold-standard, single treatment available for depression in MS. Pharmacotherapy, cognitive behavior therapy (CBT), and exercise training individually are moderately, yet incompletely, efficacious for managing depression in the general population and MS.</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">PURPOSE: This review provides an overview of evidence from meta-analyses and systematic reviews for current treatments of depression in persons with MS. This review further develops the rationale for using a combinatory treatment approach in persons with MS.</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">METHODS: We performed a narrative review of meta-analyses and systematic reviews regarding the current state of evidence for the three most common treatments of depression in persons with MS (i.e., antidepressant medication, cognitive-behavior therapy, and exercise training). We provide a concise assessment of the overall effect of these treatments on depression in the general population and then persons with MS. We further note short-comings of research on these treatments for depression.</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">CONCLUSION: There is no single, gold-standard treatment for depression in MS, and we proposed that combinatory treatments should be considered for the management of depression in MS. However, there is a paucity of evidence for the use of combinatory therapy on depression and its outcomes in persons with MS, and this supports direct examination of the feasibility and efficacy of such combinatory approaches for MDD in MS.</p><p>PMID:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33780807/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210330012823&v=2.14.3\">33780807</a> | DOI:<a href=\"https://doi.org/10.1016/j.msard.2021.102904\">10.1016/j.msard.2021.102904</a></p></div>", "link": "https://pubmed.ncbi.nlm.nih.gov/33780807/#x3D;Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc&#x", "published_date": "2021-01-06T00:00:00Z", "sources": [ "PubMed" ], "teams": [ { "id": 1, "name": "Team Gregory" } ], "subjects": [ { "subject_name": "Multiple Sclerosis", "description": null } ], "publisher": "Elsevier BV", "container_title": "Multiple Sclerosis and Related Disorders", "authors": [ { "author_id": 151223, "given_name": "C. Danielle", "family_name": "Jones", "ORCID": "http://orcid.org/0000-0003-2000-8854", "country": null }, { "author_id": 247014, "given_name": "Robert", "family_name": "Motl", "ORCID": null, "country": null }, { "author_id": 163419, "given_name": "Brian M", "family_name": "Sandroff", "ORCID": "http://orcid.org/0000-0002-2013-7632", "country": "US" } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2021-03-30T05:28:24Z", "noun_phrases": [ "Depression", "multiple sclerosis", "one approach", "its management" ], "doi": "10.1016/j.msard.2021.102904", "access": "restricted", "takeaways": " Major depression disorder (MDD) and severe depression symptoms are highly prevalent in multiple sclerosis . Depression can worsen symptoms of MS and is associated with significantly reduced quality of life and increased risk of suicide .", "categories": [] }, { "article_id": 844, "title": "Comparative effectiveness of psychotherapy approaches on Death Anxiety in Multiple Sclerosis Patients. A pilot randomized controlled trial", "summary": "<div><p>Mult Scler Relat Disord. 2021 Mar 19;51:102914. doi: 10.1016/j.msard.2021.102914. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">BACKGROUND: Death anxiety (DA) in chronic diseases has occupied the human mind more than other diseases. Therefore, multiple sclerosis (MS) patients are more prone to DA due to recurrence periods.</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">OBJECTIVE: Among the psychological interventions the two approaches of logotherapy (LT) and acceptance and commitment therapy (ACT), They pay more attention and concentration on the subject of suffering. Therefore, the present study aimed to compare the effectiveness of these two approaches on DA in MS patients.</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">METHODS: The statistical population included 48 women who were diagnosed as MS patients and had medical records at Iran MS Society in Tehran, in terms of entry and exit criteria, which were selected by convenience sampling. Then they were randomly divided into two experimental groups and one control group. This plan has an independent variable at three levels including: LT, ACT and the control group. The dependent variables are the subjects' scores on the Death Attitude Profile-Revised (DAP-R) (Wong., Reker & Gesser, 1994). Therapeutic interventions included 12 sessions of 2 h per week. A 3-hour workshop was held for the control group. in which patients were provided with basic information about the psychological problems of MS, but no strategy was presented. In order to obtain the results, the analysis of covariance was used and in the follow-up study, repeated measures analysis of variance with an intergroup variable (mixed model) was used.</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">RESULTS: It showed that both LT and ACT groups were able to be effective and reduce DA in comparison with the control group and such a positive effect on the improvement of DA was evident both in the post-test and follow-up stages. However, no significant differences were observed in comparing the effectiveness of the two intervention methods, so both methods were effective in reducing DA due to the nature of suffering.</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">CONCLUSION: Considering the effectiveness of LT and ACT in reducing DA in MS patients, the results of this study can be used in order to achieve therapeutic goals and reduce psychological problems in chronic diseases.</p><p>PMID:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33780806/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210330012823&v=2.14.3\">33780806</a> | DOI:<a href=\"https://doi.org/10.1016/j.msard.2021.102914\">10.1016/j.msard.2021.102914</a></p></div>", "link": "https://pubmed.ncbi.nlm.nih.gov/33780806/#x3D;Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc&#x", "published_date": "2021-01-06T00:00:00Z", "sources": [ "PubMed" ], "teams": [ { "id": 1, "name": "Team Gregory" } ], "subjects": [ { "subject_name": "Multiple Sclerosis", "description": null } ], "publisher": "Elsevier BV", "container_title": "Multiple Sclerosis and Related Disorders", "authors": [ { "author_id": 153336, "given_name": "Behnam", "family_name": "Lotfifar", "ORCID": "http://orcid.org/0000-0001-9958-3928", "country": null }, { "author_id": 153337, "given_name": "Ezatolah", "family_name": "Ghadampour", "ORCID": "http://orcid.org/0000-0003-3120-384X", "country": "IR" }, { "author_id": 153338, "given_name": "Nasrin", "family_name": "Bagheri", "ORCID": "http://orcid.org/0000-0002-5919-2591", "country": "IR" } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2021-03-30T05:28:24Z", "noun_phrases": [ "Comparative effectiveness", "psychotherapy approaches", "Death Anxiety", "Multiple Sclerosis Patients", "A pilot", "controlled trial" ], "doi": "10.1016/j.msard.2021.102914", "access": "restricted", "takeaways": " Logotherapy (LT) and acceptance and commitment therapy (ACT) pay more attention and concentration on the subject of suffering . Both methods were effective in reducing DA due to the nature of suffering, so both methods were .", "categories": [] }, { "article_id": 845, "title": "Resting-State Brain Network Deficits in Multiple Sclerosis Participants: Evidence from Electroencephalography and Graph Theoretical Analysis", "summary": "<div><p>Brain Connect. 2021 Mar 29. doi: 10.1089/brain.2020.0857. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\"><b><i>Background:</i></b> Multiple sclerosis (MS) is a chronic inflammatory disease leading to demyelination and axonal loss in the central nervous system that causes focal lesions of gray and white matter. However, the functional impairments of brain networks in this disease are still unspecified and need to be clearer. <b><i>Materials and Methods:</i></b> In the present study, we investigate the resting-state brain network impairments for MS participants in comparison to a normal group using electroencephalography (EEG) and graph theoretical analysis with a source localization method. Thirty-four age- and gender-matched participants from each MS group and normal group participated in this study. We recorded 5 min of EEG in the resting-state eyes open condition for each participant. One min (15 equal 4-sec artifact-free segments) of the EEG signals were selected for each participant, and the Low-Resolution Electromagnetic Tomography software was employed to calculate the functional connectivity among whole cortical regions in six frequency bands (delta, theta, alpha, beta1, beta2, and beta3). Graph theoretical analysis was used to calculate the clustering coefficient (<i>CL</i>), betweenness centrality (<i>BC</i>), shortest path length (<i>SPL</i>), and small-world propensity (<i>SWP</i>) for weighted connectivity matrices. Nonparametric permutation tests were utilized to compare these measures between groups. <b><i>Results:</i></b> Significant differences between the MS group and the normal group in the average of <i>BC</i> and <i>SWP</i> were found in the alpha band. The significant differences in the <i>BC</i> were spread over all lobes. <b><i>Conclusion:</i></b> These results suggest that the resting-state brain network for the MS group is disrupted in local and global scales, and EEG has the capability of revealing these impairments.</p><p>PMID:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33780635/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210330012823&v=2.14.3\">33780635</a> | DOI:<a href=\"https://doi.org/10.1089/brain.2020.0857\">10.1089/brain.2020.0857</a></p></div>", "link": "https://pubmed.ncbi.nlm.nih.gov/33780635/#x3D;Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc&#x", "published_date": "2021-01-06T00:00:00Z", "sources": [ "PubMed" ], "teams": [ { "id": 1, "name": "Team Gregory" } ], "subjects": [ { "subject_name": "Multiple Sclerosis", "description": null } ], "publisher": "Mary Ann Liebert Inc", "container_title": "Brain Connectivity", "authors": [ { "author_id": 247008, "given_name": "Mojtaba", "family_name": "Jouzizadeh", "ORCID": null, "country": null }, { "author_id": 247009, "given_name": "Amir Hossein", "family_name": "Ghaderi", "ORCID": null, "country": null }, { "author_id": 225254, "given_name": "Hamed", "family_name": "Cheraghmakani", "ORCID": "http://orcid.org/0000-0001-6583-3757", "country": null }, { "author_id": 201922, "given_name": "Seyed Mohammad", "family_name": "Baghbanian", "ORCID": "http://orcid.org/0000-0002-8138-7504", "country": null }, { "author_id": 247011, "given_name": "Reza", "family_name": "Khanbabaie", "ORCID": null, "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2021-03-30T05:28:24Z", "noun_phrases": [ "Resting-State Brain Network Deficits", "Multiple Sclerosis Participants", "Evidence", "Electroencephalography", "Graph Theoretical Analysis" ], "doi": "10.1089/brain.2020.0857", "access": "restricted", "takeaways": " Multiple sclerosis (MS) is a chronic inflammatory disease leading to demyelination and axonal loss in the central nervous system . The functional impairments of brain networks in this disease are still unspecified and need to be clearer .", "categories": [] }, { "article_id": 838, "title": "MRI findings in blinded trials should be available to treating physicians - Yes", "summary": "<div><p>Mult Scler. 2021 Mar 29:1352458520984744. doi: 10.1177/1352458520984744. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p>PMID:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33779365/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210330000823&v=2.14.3\">33779365</a> | DOI:<a href=\"https://doi.org/10.1177/1352458520984744\">10.1177/1352458520984744</a></p></div>", "link": "https://pubmed.ncbi.nlm.nih.gov/33779365/#x3D;Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc&#x", "published_date": "2021-01-05T00:00:00Z", "sources": [ "PubMed" ], "teams": [ { "id": 1, "name": "Team Gregory" } ], "subjects": [ { "subject_name": "Multiple Sclerosis", "description": null } ], "publisher": "SAGE Publications", "container_title": "Multiple Sclerosis Journal", "authors": [ { "author_id": 147248, "given_name": "Sandra", "family_name": "Vukusic", "ORCID": "http://orcid.org/0000-0001-7337-7122", "country": null }, { "author_id": 167428, "given_name": "Christine", "family_name": "Lebrun-Frénay", "ORCID": "http://orcid.org/0000-0002-3713-2416", "country": "FR" } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2021-03-30T04:08:25Z", "noun_phrases": [ "MRI findings", "blinded trials", "physicians" ], "doi": "10.1177/1352458520984744", "access": "restricted", "takeaways": "", "categories": [] }, { "article_id": 841, "title": "Alemtuzumab treatment in Denmark: A national study based on the Danish Multiple Sclerosis Registry", "summary": "<div><p>Mult Scler. 2021 Mar 29:13524585211003291. doi: 10.1177/13524585211003291. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">OBJECTIVE: To investigate clinical outcomes in a real-world setting in the complete population-based cohort of alemtuzumab-treated MS patients in Denmark.</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">METHODS: Data were retrieved from The Danish Multiple Sclerosis Registry between 2009 and 2019. Demographic and disease-specific patient parameters related to treatment history, efficacy, and safety outcomes were assessed at baseline and during follow-up visits.</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">RESULTS: A total of 209 patients (78% female) started treatment with alemtuzumab during the study period with 3.1 ± 1.4 years follow-up. After 2 years, 75% of patients were relapse-free compared to 48% the year before alemtuzumab (<i>p</i> < 0.001). The annual number of relapses was reduced by 69% in year 4 compared with the year prior alemtuzumab. More active disease before alemtuzumab increased the annual hazard rate for relapse (HR: 2.88, <i>p</i> < 0.001). The Expanded Disability Status Scale (EDSS) score remained stable or improved in 81% of patients after 2 years. The need for an additional treatment course was associated with higher number of relapses in the year before alemtuzumab (odds ratio (OR) = 1.95, <i>p</i> = 0.001).</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">CONCLUSION: In a country with primarily escalation strategy, relapse rate reduction was maintained for 5 years, and EDSS stabilized/improved in majority of patients. Higher relapse rate 1 year before alemtuzumab increased the odds for additional courses. Novel serious AEs were not observed.</p><p>PMID:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33779361/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210330000823&v=2.14.3\">33779361</a> | DOI:<a href=\"https://doi.org/10.1177/13524585211003291\">10.1177/13524585211003291</a></p></div>", "link": "https://pubmed.ncbi.nlm.nih.gov/33779361/#x3D;Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc&#x", "published_date": "2021-01-12T00:00:00Z", "sources": [ "PubMed" ], "teams": [ { "id": 1, "name": "Team Gregory" } ], "subjects": [ { "subject_name": "Multiple Sclerosis", "description": null } ], "publisher": "SAGE Publications", "container_title": "Multiple Sclerosis Journal", "authors": [ { "author_id": 184413, "given_name": "A", "family_name": "Theodorsdottir", "ORCID": "http://orcid.org/0000-0001-7894-611X", "country": null }, { "author_id": 247019, "given_name": "Birgit", "family_name": "Debrabant", "ORCID": null, "country": null }, { "author_id": 167429, "given_name": "Melinda", "family_name": "Magyari", "ORCID": "http://orcid.org/0000-0002-0972-5222", "country": null }, { "author_id": 324613, "given_name": "Matthias", "family_name": "Kant", "ORCID": "http://orcid.org/0000-0001-5090-8234", "country": "DK" }, { "author_id": 240415, "given_name": "Peter V", "family_name": "Rasmussen", "ORCID": null, "country": null }, { "author_id": 247021, "given_name": "Carl-Fredrik", "family_name": "Malmberg", "ORCID": null, "country": null }, { "author_id": 247022, "given_name": "Iver A", "family_name": "Norberg", "ORCID": null, "country": null }, { "author_id": 247023, "given_name": "Victoria", "family_name": "Hansen", "ORCID": null, "country": null }, { "author_id": 247024, "given_name": "Danny", "family_name": "Bech", "ORCID": null, "country": null }, { "author_id": 247025, "given_name": "Mathias F", "family_name": "Schmidt", "ORCID": null, "country": null }, { "author_id": 247026, "given_name": "Karen", "family_name": "Schreiber", "ORCID": null, "country": null }, { "author_id": 247027, "given_name": "Jette L", "family_name": "Frederiksen", "ORCID": null, "country": null }, { "author_id": 160395, "given_name": "Finn", "family_name": "Sellebjerg", "ORCID": "http://orcid.org/0000-0002-1333-9623", "country": null }, { "author_id": 163649, "given_name": "Zsolt", "family_name": "Illes", "ORCID": "http://orcid.org/0000-0001-9655-0450", "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2021-03-30T04:08:25Z", "noun_phrases": [ "Alemtuzumab treatment", "Denmark", "A national study", "the Danish Multiple Sclerosis Registry" ], "doi": "10.1177/13524585211003291", "access": "restricted", "takeaways": " After 2 years, 75% of patients were relapse-free compared to 48% the year before alemtuzumab . Annual number of relapses was reduced by 69% in year 4 compared with the year prior . The Expanded Disability Status Scale (EDSS) score remained stable or improved . Novel serious serious AEs were not observed .", "categories": [ { "category_id": 2, "category_description": "LEMTRADA, or Alemtuzumab, is a prescription medicine used to treat relapsing forms of multiple sclerosis (MS), to include relapsing-remitting disease and active secondary progressive disease, in adults. Since treatment with LEMTRADA can increase your risk of getting certain conditions and diseases, LEMTRADA is generally prescribed for people who have tried 2 or more MS medicines that have not worked well enough. LEMTRADA is not recommended for use in patients with clinically isolated syndrome (CIS). It is not known if LEMTRADA is safe and effective for use in children under 17 years of age.\n\nhttps://www.lemtrada.com/", "category_name": "Alemtuzumab", "category_slug": "alemtuzumab", "category_terms": [ "alemtuzumab", "lemtrada" ], "article_count": 118 } ] }, { "article_id": 840, "title": "Meningeal inflammation in multiple sclerosis induces phenotypic changes in cortical microglia that differentially associate with neurodegeneration", "summary": "<div><p>Acta Neuropathol. 2021 Mar 29. doi: 10.1007/s00401-021-02293-4. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">Meningeal inflammation strongly associates with demyelination and neuronal loss in the underlying cortex of progressive MS patients, thereby contributing significantly to clinical disability. However, the pathological mechanisms of meningeal inflammation-induced cortical pathology are still largely elusive. By extensive analysis of cortical microglia in post-mortem progressive MS tissue, we identified cortical areas with two MS-specific microglial populations, termed MS1 and MS2 cortex. The microglial population in MS1 cortex was characterized by a higher density and increased expression of the activation markers HLA class II and CD68, whereas microglia in MS2 cortex showed increased morphological complexity and loss of P2Y12 and TMEM119 expression. Interestingly, both populations associated with inflammation of the overlying meninges and were time-dependently replicated in an in vivo rat model for progressive MS-like chronic meningeal inflammation. In this recently developed animal model, cortical microglia at 1-month post-induction of experimental meningeal inflammation resembled microglia in MS1 cortex, and microglia at 2 months post-induction acquired a MS2-like phenotype. Furthermore, we observed that MS1 microglia in both MS cortex and the animal model were found closely apposing neuronal cell bodies and to mediate pre-synaptic displacement and phagocytosis, which coincided with a relative sparing of neurons. In contrast, microglia in MS2 cortex were not involved in these synaptic alterations, but instead associated with substantial neuronal loss. Taken together, our results show that in response to meningeal inflammation, microglia acquire two distinct phenotypes that differentially associate with neurodegeneration in the progressive MS cortex. Furthermore, our in vivo data suggests that microglia initially protect neurons from meningeal inflammation-induced cell death by removing pre-synapses from the neuronal soma, but eventually lose these protective properties contributing to neuronal loss.</p><p>PMID:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33779783/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210330000823&v=2.14.3\">33779783</a> | DOI:<a href=\"https://doi.org/10.1007/s00401-021-02293-4\">10.1007/s00401-021-02293-4</a></p></div>", "link": "https://pubmed.ncbi.nlm.nih.gov/33779783/#x3D;Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc&#x", "published_date": "2021-01-06T00:00:00Z", "sources": [ "PubMed" ], "teams": [ { "id": 1, "name": "Team Gregory" } ], "subjects": [ { "subject_name": "Multiple Sclerosis", "description": null } ], "publisher": "Springer Science and Business Media LLC", "container_title": "Acta Neuropathologica", "authors": [ { "author_id": 175989, "given_name": "Lynn", "family_name": "van Olst", "ORCID": "http://orcid.org/0000-0001-7569-0470", "country": null }, { "author_id": 175990, "given_name": "Carla", "family_name": "Rodriguez-Mogeda", "ORCID": "http://orcid.org/0000-0002-7849-9302", "country": null }, { "author_id": 295780, "given_name": "Carmen", "family_name": "Picon", "ORCID": null, "country": null }, { "author_id": 263914, "given_name": "Svenja", "family_name": "Kiljan", "ORCID": null, "country": null }, { "author_id": 295781, "given_name": "Rachel E.", "family_name": "James", "ORCID": null, "country": null }, { "author_id": 175991, "given_name": "Alwin", "family_name": "Kamermans", "ORCID": "http://orcid.org/0000-0002-3601-395X", "country": null }, { "author_id": 295782, "given_name": "Susanne M. A.", "family_name": "van der Pol", "ORCID": null, "country": null }, { "author_id": 295783, "given_name": "Lydian", "family_name": "Knoop", "ORCID": null, "country": null }, { "author_id": 273416, "given_name": "Iliana", "family_name": "Michailidou", "ORCID": null, "country": null }, { "author_id": 295784, "given_name": "Evelien", "family_name": "Drost", "ORCID": null, "country": null }, { "author_id": 295785, "given_name": "Marc", "family_name": "Franssen", "ORCID": null, "country": null }, { "author_id": 191536, "given_name": "Geert J.", "family_name": "Schenk", "ORCID": "http://orcid.org/0000-0002-9984-120X", "country": null }, { "author_id": 199658, "given_name": "Jeroen J. G.", "family_name": "Geurts", "ORCID": "http://orcid.org/0000-0002-4367-4641", "country": "CH" }, { "author_id": 197689, "given_name": "Sandra", "family_name": "Amor", "ORCID": "http://orcid.org/0000-0001-6169-9845", "country": null }, { "author_id": 295786, "given_name": "Nicholas D.", "family_name": "Mazarakis", "ORCID": null, "country": null }, { "author_id": 164525, "given_name": "Jack", "family_name": "van Horssen", "ORCID": "http://orcid.org/0000-0003-4078-7402", "country": null }, { "author_id": 254964, "given_name": "Helga E.", "family_name": "de Vries", "ORCID": null, "country": null }, { "author_id": 172132, "given_name": "Richard", "family_name": "Reynolds", "ORCID": "http://orcid.org/0000-0003-4622-4694", "country": "GB" }, { "author_id": 200460, "given_name": "Maarten E.", "family_name": "Witte", "ORCID": "http://orcid.org/0000-0002-1407-6220", "country": "NL" } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2021-03-30T04:08:25Z", "noun_phrases": [ "Meningeal inflammation", "multiple sclerosis", "phenotypic changes", "cortical microglia", "that", "neurodegeneration" ], "doi": "10.1007/s00401-021-02293-4", "access": "open", "takeaways": " Meningeal inflammation strongly associates with demyelination and neuronal loss in the underlying cortex of progressive MS patients . MS1 cortex was characterized by a higher density and increased expression of the activation markers HLA class II and CD68 . MS2 cortex showed increased morphological complexity and loss of P2Y12 and TMEM119 expression .", "categories": [] } ] }